Comparison 5. Sensitivity analysis ‐ all AAV together.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 Mortality	4	438	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.25 [0.64, 7.93]
5.1.1 EGPA	1	136	Peto Odds Ratio (Peto, Fixed, 95% CI)	7.39 [0.15, 372.38]
5.1.2 GPA active drug vs placebo	2	285	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.45 [0.55, 10.97]
5.1.3 GPA infliximab vs rituximab	1	17	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.88 [0.05, 15.51]
5.2 Any remission	3	333	Risk Ratio (M‐H, Random, 95% CI)	1.17 [0.36, 3.76]
5.2.1 EGPA	1	136	Risk Ratio (M‐H, Random, 95% CI)	2.77 [1.62, 4.74]
5.2.2 GPA active drug vs placebo	1	180	Risk Ratio (M‐H, Random, 95% CI)	0.97 [0.89, 1.07]
5.2.3 GPA infliximab vs rituximab	1	17	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.11, 1.81]
5.3 Durable remission	3	327	Risk Ratio (M‐H, Random, 95% CI)	1.31 [0.20, 8.61]
5.3.1 EGPA	1	136	Risk Ratio (M‐H, Random, 95% CI)	13.00 [1.75, 96.63]
5.3.2 GPA active drug vs placebo	1	174	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.77, 1.11]
5.3.3 GPA infliximab vs rituximab	1	17	Risk Ratio (M‐H, Random, 95% CI)	0.22 [0.03, 1.60]
5.4 Disease relapse	2	241	Risk Ratio (M‐H, Random, 95% CI)	0.68 [0.54, 0.86]
5.4.1 EGPA	1	136	Risk Ratio (M‐H, Random, 95% CI)	0.68 [0.53, 0.86]
5.4.2 GPA active drug vs placebo	1	105	Risk Ratio (M‐H, Random, 95% CI)	0.74 [0.27, 1.97]
5.5 Any serious or severe AE	4	438	Risk Ratio (M‐H, Random, 95% CI)	0.96 [0.78, 1.20]
5.5.1 EGPA	1	136	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.35, 1.28]
5.5.2 GPA active drug vs placebo	2	285	Risk Ratio (M‐H, Random, 95% CI)	1.00 [0.80, 1.27]
5.5.3 Infliximab vs rituximab	1	17	Risk Ratio (M‐H, Random, 95% CI)	1.78 [0.20, 16.10]
5.6 Any withdrawals due to AE	4	438	Risk Ratio (M‐H, Random, 95% CI)	2.57 [1.13, 5.83]
5.6.1 EGPA	1	136	Risk Ratio (M‐H, Random, 95% CI)	2.00 [0.19, 21.54]
5.6.2 GPA active drug vs placebo	2	285	Risk Ratio (M‐H, Random, 95% CI)	2.66 [1.07, 6.59]
5.6.3 GPA infliximab vs rituximab	1	17	Risk Ratio (M‐H, Random, 95% CI)	2.70 [0.13, 58.24]